Abstract:Adjuvants potentiate antigen-specific protective immune responses and can be key elements promoting vaccine effectiveness. We previously reported that the Onchocerca volvulus recombinant protein rOv-ASP-1 can induce activation and maturation of naïve human DCs and therefore could be used as an innate adjuvant to promote balanced Th1 and Th2 responses to bystander vaccine antigens in mice. With a few vaccine antigens, it also promoted a Th1-biased response based on pronounced induction of Th1-associated IgG2a and IgG2b antibody responses and the upregulated production of Th1 cytokines, including IL-2, IFN-γ, TNF-α and IL-6. However, because it is a protein, the rOv-ASP-1 adjuvant may also induce anti-self-antibodies. Therefore, it was important to verify that the host responses to self will not affect the adjuvanticity of rOv-ASP-1 when it is used in subsequent vaccinations with the same or different vaccine antigens. In this study, we have established rOv-ASP-1's adjuvanticity in mice during the course of two sequential vaccinations using two vaccine model systems: the receptor-binding domain (RBD) of SARS-CoV spike protein and a commercial influenza virus hemagglutinin (HA) vaccine comprised of three virus strains. Moreover, the adjuvanticity of rOv-ASP-1 was retained with an efficacy similar to that obtained when it was used for a first vaccination, even though a high level of anti-rOv-ASP-1 antibodies was present in the sera of mice before the administration of the second vaccine. To further demonstrate its utility as an adjuvant for human use, we also immunized non-human primates (NHPs) with RBD plus rOv-ASP-1 and showed that rOv-ASP-1 could induce high titres of functional and protective anti-RBD antibody responses in NHPs. Notably, the rOv-ASP-1 adjuvant did not induce high titer antibodies against self in NHPs. Thus, the present study provided a sound scientific foundation for future strategies in the development of this novel protein adjuvant.

Recombinant<i>Ov</i>-ASP-1, a Th1-Biased Protein Adjuvant Derived from the Helminth<i>Onchocerca volvulus</i>, Can Directly Bind and Activate Antigen-Presenting Cells

Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.

Rov-Asp-1, a Recombinant Secreted Protein of the Helminth Onchocercavolvulus, is a Potent Adjuvant for Inducing Antibodies to Ovalbumin, HIV-1 Polypeptide and SARS-CoV Peptide Antigens

The Adjuvanticity of an O. Volvulus-Derived Rov-Asp-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates

A Truncated Fragment of Ov-Asp-1 Consisting of the Core Pathogenesis-Related-1 (Pr-1) Domain Maintains Adjuvanticity As the Full-Length Protein

IL-17 As an Adjuvant Enhances Immune Responses of Recombinant Protein Vaccine

Novel Polysaccharide Adjuvant from the Roots of Actinidia Eriantha with Dual Th1 and Th2 Potentiating Activity.

Adjuvant effect of ginsenoside Rg1

Orf virus as an adjuvant enhances the immune response to a PCV2 subunit vaccine

Induction of Protection Against Divergent H5N1 Influenza Viruses Using a Recombinant Fusion Protein Linking Influenza M2e to Onchocerca Volvulus Activation Associated Protein-1 (ASP-1) Adjuvant

Ginsenoside Rg1 Enhances Immune Response Induced by Recombinant Toxoplasma Gondii SAG1 Antigen.

Priming with Raav Encoding Rbd of Sars-Cov S Protein and Boosting with Rbd-Specific Peptides for T Cell Epitopes Elevated Humoral and Cellular Immune Responses Against Sars-Cov Infection

Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response

Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation

Phosphorothioated Antisense Oligodeoxynucleotide Suppressing Interleukin-10 is a Safe and Potent Vaccine Adjuvant.

A Click‐Type Enzymatic Method for Antigen‐Adjuvant Conjugation

[Immune Response Induced by Vaccination with Pseudotyped Raav1 Expressing HPV16 L1 Protein].

Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins

Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity

A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines

Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.